Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Here’s Why

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s stock price hit a new 52-week low during trading on Thursday . The company traded as low as $18.39 and last traded at $18.41, with a volume of 45587 shares trading hands. The stock had previously closed at $19.30.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. TD Cowen initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price target for the company. Wall Street Zen cut Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. William Blair initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, Leerink Partners began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Trading Down 5.8%

The company has a market capitalization of $2.36 billion and a P/E ratio of -0.00. The stock has a 50 day moving average of $21.01.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings data on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Kailera Therapeutics

In other news, Director Adam Koppel purchased 1,562,500 shares of the stock in a transaction on Monday, April 20th. The stock was purchased at an average price of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the transaction, the director owned 22,583,268 shares in the company, valued at approximately $361,332,288. The trade was a 7.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Rtw Investments, Lp purchased 500,000 shares of the company’s stock in a transaction on Monday, April 20th. The shares were purchased at an average price of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the purchase, the insider directly owned 10,776,820 shares of the company’s stock, valued at $172,429,120. The trade was a 4.87% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 10,460,938 shares of company stock valued at $167,375,008.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.